- Home
- NYC vs LIXT Comparison
NYC vs LIXT Comparison
Compare NYC & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- LIXT
- Stock Information
- Founded
- NYC 2013
- LIXT 2005
- Country
- NYC United States
- LIXT United States
- Employees
- NYC N/A
- LIXT N/A
- Industry
- NYC Real Estate
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- LIXT Health Care
- Exchange
- NYC Nasdaq
- LIXT Nasdaq
- Market Cap
- NYC 25.4M
- LIXT 20.5M
- IPO Year
- NYC N/A
- LIXT N/A
- Fundamental
- Price
- NYC $8.05
- LIXT $4.20
- Analyst Decision
- NYC
- LIXT
- Analyst Count
- NYC 0
- LIXT 0
- Target Price
- NYC N/A
- LIXT N/A
- AVG Volume (30 Days)
- NYC 3.3K
- LIXT 75.1K
- Earning Date
- NYC 11-14-2025
- LIXT 11-07-2025
- Dividend Yield
- NYC N/A
- LIXT N/A
- EPS Growth
- NYC N/A
- LIXT N/A
- EPS
- NYC N/A
- LIXT N/A
- Revenue
- NYC $54,865,000.00
- LIXT N/A
- Revenue This Year
- NYC $8.40
- LIXT N/A
- Revenue Next Year
- NYC $1.62
- LIXT N/A
- P/E Ratio
- NYC N/A
- LIXT N/A
- Revenue Growth
- NYC N/A
- LIXT N/A
- 52 Week Low
- NYC $7.20
- LIXT $0.64
- 52 Week High
- NYC $16.30
- LIXT $6.26
- Technical
- Relative Strength Index (RSI)
- NYC 30.14
- LIXT 45.52
- Support Level
- NYC $7.20
- LIXT $4.20
- Resistance Level
- NYC $8.05
- LIXT $4.97
- Average True Range (ATR)
- NYC 0.39
- LIXT 0.36
- MACD
- NYC -0.12
- LIXT 0.02
- Stochastic Oscillator
- NYC 30.15
- LIXT 33.19
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.